Effectiveness of Thermal-Pneumatic Airfoil-Ice-Protection System

Icing and drag investigations were conducted in the NACA Lewis icing research tunnel employing a combination thermal-pneumatic de-icer mounted on a 42-inch-chord NACA 0018 airfoil. The de-icer consisted of a 3-inch-wide electrically heated strip symmetrically located about the leading edge with inflatable tubes on the upper and lower airfoil surfaces aft of the heated area. The entire de-icer extended to approximately 25 percent of chord. A maximum power density of 9.25 watts per square inch was required for marginal ice protection on the airfoil leading edge at an air temperature of 00 F and an airspeed of 300 miles per hour. Drag measurements indicated, that without icing, the de-icer installation increased the section drag to approximately 140 percent of that of the bare airfoil; with the tubes inflated, this value increased to a maximum of approximately 620 percent. A 2-minute tube-inflation cycle prevented excessive ice formation on the inflatable area although small scattered residual Ice formations remained after inflation and were removed intermittently during later cycles. Effects of the time lag of heater temperatures after initial application of power and the insulating effect of ice formations on heater temperatures were also determined

Evaluation of thermal soak times

A mathematical model for the heat transfer within the electronics package of a Chaparral missile was performed. The Grashof number for this configuration was less than 2000 which indicated that the primary mode of heat transfer was conduction. The Vodicka theory for heat conduction in laminated composite media was utilized to obtain the solution for the model

How well do we currently care for our dying patients in acute hospitals: the views of the bereaved relatives?

Background The National Care of the Dying Audit—Hospitals (NCDAH) is used as a method to evaluate care for dying patients in England. An additional component to the 2013/2014 audit was the Local Survey of Bereaved Relatives Views using the ‘Care Of the Dying Evaluation’ (CODE) questionnaire. Aim Within the context of the NCDAH audit, to evaluate quality of care provided to dying patients and their families in acute hospitals from the perspective of bereaved relatives. Design Postbereavement survey to bereaved relatives. Setting/participants For acute hospitals wishing to participate, consecutive ‘expected’ adult deaths occurring between 1 May and 30 June 2013 were identified and the CODE questionnaire was sent to the next-of-kin. Results From 3414 eligible next-of-kin, 95 (2.8%) were excluded due to being involved in a complaint procedure and 1006 (29.5%) due to insufficient next-of-kin details. From the remaining 2313 potential participants, 858 returned a completed CODE questionnaire (37.1% response rate). Generally, symptoms were perceived to be well controlled with 769 (91%) participants reporting that either no pain was present or only there ‘some of the time’. Unmet information needs, however, was a recognised area for improvement, for example, 230 (29%) reporting having a discussion about hydration would have been beneficial. Conclusions Adopting a postbereavement survey to NCDAH appears to be feasible, acceptable and a valuable addition. On the whole, the majority of participants reported good or excellent care. A small but significant minority, however, perceived poor quality of patient care with clear and timely communication urgently needed

Educating for Entrepreneurial Leadership: From Didacticism to Co-creation

Entrepreneurial leadership promotes organisational competitive advantage and innovation resulting in increased attention on entrepreneurial leadership development. Many higher education institutions (HEIs) claim to develop entrepreneurial leaders. However, knowledge of how to facilitate entrepreneurial leadership development is limited, the effectiveness of development practices is contestable, and current understanding of the phenomenon is mostly conceptual. We address this void by exploring educators’ perspectives of entrepreneurial leadership development and consider how the phenomenon is facilitated. We employ Interpretative Phenomenological Analysis (IPA) as our research methodology and analyse the data following IPA data analysis guidance. Findings signify the importance of placing strong emphasis on co-creating education experience with wider stakeholder involvement, thereby forming an entrepreneurial community which works collectively over the longer-term to facilitate entrepreneurial leadership development. The findings also reveal the pedagogic significance of facilitating supportive learning conditions and ‘handholding,’ a broader form of support which contradicts the established notion of ‘independent learners’ thereby challenging current ontologies around ‘student support’ when facilitating entrepreneurial leadership development

Ipilimumab and Bevacizumab in Glioblastoma

The median survival in glioblastoma is just over a year, with no standard second-line therapy. Ipilimumab is an immune checkpoint inhibitor that activates the anti-tumour immune response by cytotoxic T-lymphocyte antigen-4 blockade. There is significant evidence supporting its role in the treatment of malignant melanoma, including in patients with brain metastases. The addition of the anti-angiogenesis agent, bevacizumab, seems to offer additional benefit and limit the immune-related side-effects of ipilimumab in melanoma. To date there have been no clinical trials investigating this combination in glioblastoma. In this single practice case series, 20 patients with glioblastoma were consented for and treated with ipilimumab and bevacizumab in combination. Safety, tolerability and the response to treatment were reviewed for all patients. Three patients were treated after palliative first-line radiotherapy, one patient after first-line chemoradiation and 16 patients were treated with recurrent disease. Sixty-five per cent of patients completed four cycles of 3 weekly ipilimumab therapy, administered with 2 weekly bevacizumab. Radiographic responses for patients with recurrent disease were evaluated by Response Assessment in Neuro-oncology (RANO) criteria; 31% of patients showed a partial response, 31% had stable disease and 38% had disease progression. The treatment combination was well tolerated, with treatment terminated before completion due to adverse events in two patients. Autoimmune toxicity was manageable with systemic corticosteroid therapy. Ipilimumab and bevacizumab in combination show promising activity with a predictable and manageable toxicity profile, warranting further clinical studies